Pieter Rottiers

Summary

Publications

  1. ncbi Modulation of gut-associated lymphoid tissue functions with genetically modified Lactococcus lactis
    Pieter Rottiers
    ActoGeniX N V, Zwijnaarde, Belgium
    Int Rev Immunol 28:465-86. 2009
  2. ncbi AG013, a mouth rinse formulation of Lactococcus lactis secreting human Trefoil Factor 1, provides a safe and efficacious therapeutic tool for treating oral mucositis
    Silvia Caluwaerts
    ActoGeniX N V, Technologiepark 4, B 9052 Ghent Zwijnaarde, Belgium
    Oral Oncol 46:564-70. 2010
  3. ncbi Actobiotics as a novel method for cytokine delivery
    Lothar Steidler
    ActoGeniX NV, Zwijnaarde, Belgium
    Ann N Y Acad Sci 1182:135-45. 2009

Collaborators

  • Lothar Steidler
  • Silvia Caluwaerts
  • Bernard Coulie
  • Sam Corveleyn
  • Brynmor Watkins
  • Stephen Sonis
  • Peter Vanhoenacker
  • Sabine Neirynck
  • Klaas Vandenbroucke

Detail Information

Publications3

  1. ncbi Modulation of gut-associated lymphoid tissue functions with genetically modified Lactococcus lactis
    Pieter Rottiers
    ActoGeniX N V, Zwijnaarde, Belgium
    Int Rev Immunol 28:465-86. 2009
    ..The therapeutic applications of these genetically modified strains are discussed, with special regards to immunomodulation...
  2. ncbi AG013, a mouth rinse formulation of Lactococcus lactis secreting human Trefoil Factor 1, provides a safe and efficacious therapeutic tool for treating oral mucositis
    Silvia Caluwaerts
    ActoGeniX N V, Technologiepark 4, B 9052 Ghent Zwijnaarde, Belgium
    Oral Oncol 46:564-70. 2010
    ..lactis bacteria provides a safe and efficacious therapeutic tool for the prevention and treatment of OM...
  3. ncbi Actobiotics as a novel method for cytokine delivery
    Lothar Steidler
    ActoGeniX NV, Zwijnaarde, Belgium
    Ann N Y Acad Sci 1182:135-45. 2009
    ..lactis- ActoBiotics- in clinical practice. Here we discuss the development of recombinant L. lactis for intestinal delivery of rhIL-10 in humans...